NeuroCog Trials, Inc. announced today that work they completed while operating within Duke University for the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Project, a multi-site NIMH-sponsored clinical trial in patients with Alzheimer’s disease, were published today in the American
Journal of Psychiatry. The assessment of changes in cognition is central to Alzheimer’s therapies, and the standard tests to detect these changes are prone to both errors in administration and scoring. NeuroCog Trials’ services address these challenges by helping sites collect high quality neuropsychological data, which in turn help sponsors decide whether to stop the development of ineffective therapies or fuel the development of effective therapies.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, and one of the authors of the resulting publication from the trial, said, “We were pleased that the services we provided for the CATIE Project helped to enhance data quality for this multi-site clinical trial. As NeuroCog Trials continues to grow, our therapeutic areas have expanded from our historic focus on psychiatric clinical trials to address sponsors’ needs in a variety of other diagnostic categories, including Alzheimer’s disease.”